Among 9324 patients, anti-PD-(L)1 agents were associated with a moderate risk of anaemia (10%) and a low risk of neutropenia and thrombocytopenia (0.9% and 2.8%, respectively), with negligible risk of febrile neutropenia (0.45%). This evidence concerns the gene CD274 and anemia (phenotype).